Copyright
©The Author(s) 2018.
World J Gastroenterol. Dec 21, 2018; 24(47): 5322-5330
Published online Dec 21, 2018. doi: 10.3748/wjg.v24.i47.5322
Published online Dec 21, 2018. doi: 10.3748/wjg.v24.i47.5322
Table 2 Summary of treatment results with sphingosine-1-phosphate receptor modulators, AJM300, and phospholipids in ulcerative colitis patients
Study | Drug | Study population | Treatment arm | Endoscopy endpoint | Time of observation, wk | Rate of mucosal healing |
Sandborn et al[41] | Ozanimod | Moderate to severe UC patients (n = 197) | Dose of 0.5 mg or 1 mg or placebo, once daily | Mcosal healing (endoscopy subscore ≤ 1) | At 8 wk; at 32 wk | Placebo 12% |
Ozanimod 0.5 mg = 28%, (P = 0.03) | ||||||
Ozanimod 1 mg = 34%, (P = 0.002) | ||||||
At week 8 | ||||||
Placebo 12% | ||||||
Ozanimod 0.5 mg = 32%, (P = 0.006) | ||||||
Ozanimod 1 mg = 33%, (P = 0.005) | ||||||
At week 32 | ||||||
Yoshimura et al[46] | AJM300 | Moderate to severe UC patients (n = 102) | Dose of 960 mg or placebo, 3 times daily | Mucosal healing, (endoscopic subscore of 0 or 1) | At 8 wk | Placebo 29.4% |
AJM300 960 mg = 58.8% (P = 0.0014) | ||||||
Stremmel et al[50] | Phosphatidylcholine-rich phospholipids | Chronic active, ulcerative colitis, with a clinical activity index (CAI) of > 4 (n = 60) | Dose of PC rich phospholipids (1.5 g /dose) or placebo, four times daily | Mucosal healing, was not formally assessed 48 patients were examined using the standard endoscopic activity index (EAI); Secondary end point analysis DEAI (> 50%) | At three mo | None of 29 placebo patients DEAI (> 50%) in 11 of 29 evaluated of PC patients P = 0.00016 |
Karner et al[51] | LT-02 | Ulcerative colitis patients with an inadequate response to mesalazine, a disease activity score (Simple Clinical Colitis Activity Index (SCCAI)) of ≥ 5, and bloody diarrhea (n = 156) | Dose of LT-2 (0.8, 1.6 or 3.2 g) or placebo | Mucosal healing (endoscopic Mayo Score ≤ 1) | At 12 wk | Placebo 40.0% |
LT-2 0.8 g = 57.5%, (P = 0.097) | ||||||
LT-2 1.6 g = 56.1%, (P = 0.097) | ||||||
LT-2 3.2 g = 51.4%, (P = 0.097) | ||||||
Pooled LT-02 groups 55.2 (P = 0.098) |
- Citation: Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330
- URL: https://www.wjgnet.com/1007-9327/full/v24/i47/5322.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i47.5322